Transition Therapeutics

company

About

Transition Therapeutics is a biopharmaceutical company developing novel therapeutics for disease indications with large markets.

  • 11 - 50

Details

Last Funding Type
Post-IPO Equity
Last Funding Money Raised
$30.80M
Industries
Biopharma,Biotechnology,Therapeutics
Founded date
Jan 1, 1987
Number Of Employee
11 - 50
Operating Status
Close

Transition is a biopharmaceutical company, developing novel therapeutics for disease indications with large markets. Transition's lead products include ELND005 for the treatment of Alzheimer's disease and TT223 for the treatment of diabetes. Transition has an emerging pipeline of preclinical drug candidates acquired externally and developed internally using its proprietary drug discovery engine.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
1
$30.80M
Transition Therapeutics has raised a total of $30.80M in funding over 2 rounds. Their latest funding was raised on Jun 6, 2014 from a Post-IPO Equity round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Jun 6, 2014 Post-IPO Equity $30.80M 1 Detail

Investors

Number of Lead Investors
Number of Investors
1
Transition Therapeutics is funded by 1 investors. Jack W. Schuler Living Trust are the most recent investors.
Investor Name Lead Investor Funding Round
Jack W. Schuler Living Trust Post-IPO Equity